BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/16/2020 7:58:40 AM | Browse: 701 | Download: 1194
Publication Name World Journal of Gastroenterology
Manuscript ID 50809
Country/Territory France
Received
2019-10-07 09:48
Peer-Review Started
2019-10-07 09:49
To Make the First Decision
Return for Revision
2019-11-10 05:24
Revised
2019-11-29 11:02
Second Decision
2019-12-19 02:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-12-22 01:58
Articles in Press
2019-12-22 01:58
Publication Fee Transferred
Edit the Manuscript by Language Editor
2020-01-03 18:04
Typeset the Manuscript
2020-01-13 11:39
Publish the Manuscript Online
2020-01-16 07:58
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Retrospective Study
Article Title Idarubicin vs Doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
Manuscript Source Unsolicited Manuscript
All Author List Gael Stéphane Roth, Yann Teyssier, Melodie Abousalihac, Arnaud Seigneurin, Julien Ghelfi, Christian Sengel and Thomas Decaens
ORCID
Author(s) ORCID Number
Gael Stéphane Roth http://orcid.org/0000-0001-5822-4320
Yann Teyssier http://orcid.org/0000-0002-9785-8729
Melodie Abousalihac http://orcid.org/0000-0002-0661-1684
Arnaud Seigneurin http://orcid.org/0000-0002-2168-1672
Julien Ghelfi http://orcid.org/0000-0002-9039-6488
Christian Sengel http://orcid.org/0000-0001-9004-256X
Thomas Decaens http://orcid.org/0000-0003-0928-0048
Funding Agency and Grant Number
Corresponding Author Thomas Decaens, MD, PhD, Full Professor, Department of Hepatology and Gastroenterology, Grenoble-Alpes Universitary Hospital, BP 217, Cedex 09, Grenoble 38043, France. tdecaens@chu-grenoble.fr
Key Words Hepatocellular carcinoma; Transarterial chemoembolization; Idarubicin; Doxorubicin; Intermediate stage;
Core Tip Transarterial chemoembolization in the treatment of choice of intermediate stage hepatocellular carcinoma. Doxorubicin is the most used drug without any satisfying evidence of its superiority compared with other drugs. An increasing number of preclinical and early phase clinical studies suggest the superiority of idarubicin anti tumor efficacy in transarterial chemoembolization. With the limits relative to retrospective analysis, this study shows that idarubicin represents an alternative to doxorubicin in the treatment of hepatocellular carcinoma with comparable efficacy and safety. It needs to be confirm by randomized clinical trials.
Publish Date 2020-01-16 07:58
Citation Roth GS, Teyssier Y, Abousalihac M, Seigneurin A, Ghelfi J, Sengel C, Decaens T. Idarubicin vs Doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. World J Gastroenterol 2020; 26(3): 324-334
URL https://www.wjgnet.com/1007-9327/full/v26/i3/324.htm
DOI https://dx.doi.org/10.3748/wjg.v26.i3.324
Full Article (PDF) WJG-26-324.pdf
Full Article (Word) WJG-26-324.docx
Manuscript File 50809-Review-Filipodia.docx
Answering Reviewers 50809-Answering reviewers.pdf
Audio Core Tip 50809-Audio core tip.m4a
Biostatistics Review Certificate 50809-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 50809-Conflict-of-interest statement.pdf
Copyright License Agreement 50809-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 50809-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 50809-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 50809-Language certificate.pdf
Peer-review Report 50809-Peer-review(s).pdf
Scientific Misconduct Check 50809-Scientific misconduct check.pdf
Scientific Editor Work List 50809-Scientific editor work list.pdf